Long e.t al. compared the sensitivity and specificity of the immunohistochemical staining of BRAF V600E in paraffin-embedded samples of patients with stage 4 malignant melanoma, which required the molecular confir- mation of this mutation for target therapy. This evidence concerns the gene BRAF and melanoma.